Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients

A phase II study was undertaken to determine the safety of combining flutamide with gemcitabine, with response rate being the primary end point. Twenty-seven patients with histologically proven, previously untreated, unresectable pancreatic adenocarcinoma received gemcitabine, 1 g m(−2) intravenousl...

Descripción completa

Detalles Bibliográficos
Autores principales: Corrie, P, Mayer, A, Shaw, J, D'Ath, S, Blagden, S, Blesing, C, Price, P, Warner, N
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364255/
https://www.ncbi.nlm.nih.gov/pubmed/12232752
http://dx.doi.org/10.1038/sj.bjc.6600523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364255/
https://www.ncbi.nlm.nih.gov/pubmed/12232752
http://dx.doi.org/10.1038/sj.bjc.6600523

Ejemplares similares